Price To Earnings Ratio 22.84 | Sector PE 70.08 |
PB Ratio 2.43 | Sector PB 9.24 |
EPS 54.16 | Dividend Yield 0.41 |
Today's Volume 1.038 M | 5 Day Avg. Volume 1.103 M |
PEG Ratio 0.35 | Market Cap. ₹ 73,330.00 Cr. |
Time | AUROPHARMA | VS | Industry |
---|---|---|---|
1 Day | -0.48% | 0.81% | |
1 Week | 1.34% | 3.5% | |
1 Month | -10.97% | 3.78% | |
6 Months | -5.1% | 21.84% | |
1 Year | 14.47% | 48.38% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 1237.75 | Bearish |
20 | 1285.51 | Bearish |
30 | 1334.79 | Bearish |
50 | 1395.53 | Bearish |
100 | 1431.2 | Bearish |
200 | 1282.75 | Bearish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 2434.52 | 2386.75 | 5016.48 | ||||
Investing Activities | -4255.95 | -3977.75 | -3211.56 | ||||
Financing Activities | 800.42 | 1814.41 | -2969.27 | ||||
Net Cash Flow | -1021.01 | 223.41 | -1164.35 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Aurobindo Pharma | -0.48 | 1.34 | -10.97 | -5.1 | 14.47 |
Advanced Enzyme Tech | -1.01 | 2.11 | -17.27 | -0.5 | 13.58 |
Alembic | 3.08 | 7.1 | 7.09 | 1.53 | 1.53 |
Aster DM Healthcare | -0.91 | 12.98 | 12.26 | 33.35 | 42.79 |
Divi's Laboratories | 1.5 | 1.42 | 5.93 | 33.71 | 65.09 |
Aurobindo Pharma Limited is an Indian pharmaceutical company. The main activity of the company is the production and distribution of active pharmaceutical ingredients, branded drugs, generic drugs and related services. Its product portfolio is divided into seven therapeutic/product areas which include CNS (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Oral & Sterile, anti-infective, anti-diabetic and cephalosporins - orally. It develops various oncology and hormonal products. It develops topical and transdermal products for the therapeutic segment of dermatology. The company is also developing approximately three depot injections based on microsphere and nanosuspension technology platforms. The company distributes its products worldwide in about 150 countries. The company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and others.